Real-world survival outcomes with CCM®

Study Objectives

• • •

• What is the observed real-world survival for CCM® patients and how does that benchmark against CRT?

Study Design

• • •

Retrospective analysis using Truveta™ real-world database.

[hospital] 900 hospitals
[clinic] 20k clinics
[patient] 120M + US patients

The Truveta™ real-world database was successfully validated for analysis, as demonstrated by comparable results in CRT populations for Truveta™ (74%) and CARE-HF (77%) when analyzing real-world survival rates.

Inclusion Criteria

CCM® and CRT HF populations from the Truveta™ database between Jan 2016 - Dec 2024.

n (CCM®) = 503
n (CRT) = 52,500

Results

• • •

CRT and CCM Survival (Kaplan-Meier estimates)

CRT Survival

The Kaplan-Meier survival curve for Cardiac Resynchronization Therapy (CRT) shows the following estimated survival probabilities:

• CARE - HF: 77%
• All CRT: 75%
• CRT - LVEF ≤35%: 74%

Number at Risk for CRT:

CCM Survival

The Kaplan-Meier survival curve for Cardiac Contractility Modulation (CCM) shows the following estimated survival probabilities:

• All CCM: 77%
• CCM - LVEF 25-45%: 78%

Note: LVEF 25-45% Corresponds to current CCM® indication.

Number at Risk for CCM:

* LVEF 25-45% Corresponds to current CCM® indication.